Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: Post hoc analyses of the rationale and insight for gleevec high-dose therapy study

Luke P. Akard, Jorge E. Cortes, Maher Albitar, Stuart L. Goldberg, Ghulam Warsi, Meir Wetzler, Solveig G. Ericson, Jerald P. Radich

Research output: Contribution to journalArticle

Abstract

Context: Although bone marrow (BM) karyotyping has been the standard in monitoring patients with chronic myeloid leukemia, peripheral blood (PB) monitoring methods may be more convenient.

Objective: To conduct post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study to evaluate correlations between results of cytogenetic testing and molecular monitoring from BM and PB during the first 18 months of high-dose imatinib therapy, and between early and late molecular responses.

Design: Newly diagnosed patients with chronic-phase chronic myeloid leukemia received imatinib 400 mg twice daily and were monitored quarterly for up to 18 months. Cytogenetic testing was performed by karyotyping using BM or by fluorescence in situ hybridization using PB. Molecular testing was performed by quantitative reverse transcriptase polymerase chain reaction using BM and PB.

Results: Significant pairwise correlations were found between results obtained by karyotyping, fluorescence in situ hybridization, and quantitative reverse transcriptase polymerase chain reaction using PB or BM (all pairwise correlations <0.8; P >.001). At 12 months, cytogenetic response by karyotyping correlated well with response by fluorescence in situ hybridization. A median 2.579-log reduction in BCR-ABL1 level from a standardized baseline correlated with fluorescence in situ hybridization-negative status. Patients with greater than 2-log reduction in BCRABL1 level at 3, 6, and 9 months were more likely to achieve major molecular response at 18 months than those with 2-log reduction or less.

Conclusions: Our findings support the feasibility of molecular monitoring using PB and suggest that molecular monitoring conducted at a single reliable reference laboratory can adequately track response without invasive BM testing. Our findings are consistent with other work indicating that early response to imatinib predicts favorable long-term outcome.

Original languageEnglish (US)
Pages (from-to)1186-1192
Number of pages7
JournalArchives of Pathology and Laboratory Medicine
Volume138
Issue number9
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Leukemia, Myeloid, Chronic Phase
Physiologic Monitoring
Cytogenetics
Karyotyping
Bone Marrow
Fluorescence In Situ Hybridization
Reverse Transcriptase Polymerase Chain Reaction
Therapeutics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Imatinib Mesylate

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase : Post hoc analyses of the rationale and insight for gleevec high-dose therapy study. / Akard, Luke P.; Cortes, Jorge E.; Albitar, Maher; Goldberg, Stuart L.; Warsi, Ghulam; Wetzler, Meir; Ericson, Solveig G.; Radich, Jerald P.

In: Archives of Pathology and Laboratory Medicine, Vol. 138, No. 9, 01.09.2014, p. 1186-1192.

Research output: Contribution to journalArticle

@article{9af9aad93bf44196906fe9b4aeb66343,
title = "Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: Post hoc analyses of the rationale and insight for gleevec high-dose therapy study",
abstract = "Context: Although bone marrow (BM) karyotyping has been the standard in monitoring patients with chronic myeloid leukemia, peripheral blood (PB) monitoring methods may be more convenient.Objective: To conduct post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study to evaluate correlations between results of cytogenetic testing and molecular monitoring from BM and PB during the first 18 months of high-dose imatinib therapy, and between early and late molecular responses.Design: Newly diagnosed patients with chronic-phase chronic myeloid leukemia received imatinib 400 mg twice daily and were monitored quarterly for up to 18 months. Cytogenetic testing was performed by karyotyping using BM or by fluorescence in situ hybridization using PB. Molecular testing was performed by quantitative reverse transcriptase polymerase chain reaction using BM and PB.Results: Significant pairwise correlations were found between results obtained by karyotyping, fluorescence in situ hybridization, and quantitative reverse transcriptase polymerase chain reaction using PB or BM (all pairwise correlations <0.8; P >.001). At 12 months, cytogenetic response by karyotyping correlated well with response by fluorescence in situ hybridization. A median 2.579-log reduction in BCR-ABL1 level from a standardized baseline correlated with fluorescence in situ hybridization-negative status. Patients with greater than 2-log reduction in BCRABL1 level at 3, 6, and 9 months were more likely to achieve major molecular response at 18 months than those with 2-log reduction or less.Conclusions: Our findings support the feasibility of molecular monitoring using PB and suggest that molecular monitoring conducted at a single reliable reference laboratory can adequately track response without invasive BM testing. Our findings are consistent with other work indicating that early response to imatinib predicts favorable long-term outcome.",
author = "Akard, {Luke P.} and Cortes, {Jorge E.} and Maher Albitar and Goldberg, {Stuart L.} and Ghulam Warsi and Meir Wetzler and Ericson, {Solveig G.} and Radich, {Jerald P.}",
year = "2014",
month = "9",
day = "1",
doi = "10.5858/arpa.2013-0584-OA",
language = "English (US)",
volume = "138",
pages = "1186--1192",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "9",

}

TY - JOUR

T1 - Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase

T2 - Post hoc analyses of the rationale and insight for gleevec high-dose therapy study

AU - Akard, Luke P.

AU - Cortes, Jorge E.

AU - Albitar, Maher

AU - Goldberg, Stuart L.

AU - Warsi, Ghulam

AU - Wetzler, Meir

AU - Ericson, Solveig G.

AU - Radich, Jerald P.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Context: Although bone marrow (BM) karyotyping has been the standard in monitoring patients with chronic myeloid leukemia, peripheral blood (PB) monitoring methods may be more convenient.Objective: To conduct post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study to evaluate correlations between results of cytogenetic testing and molecular monitoring from BM and PB during the first 18 months of high-dose imatinib therapy, and between early and late molecular responses.Design: Newly diagnosed patients with chronic-phase chronic myeloid leukemia received imatinib 400 mg twice daily and were monitored quarterly for up to 18 months. Cytogenetic testing was performed by karyotyping using BM or by fluorescence in situ hybridization using PB. Molecular testing was performed by quantitative reverse transcriptase polymerase chain reaction using BM and PB.Results: Significant pairwise correlations were found between results obtained by karyotyping, fluorescence in situ hybridization, and quantitative reverse transcriptase polymerase chain reaction using PB or BM (all pairwise correlations <0.8; P >.001). At 12 months, cytogenetic response by karyotyping correlated well with response by fluorescence in situ hybridization. A median 2.579-log reduction in BCR-ABL1 level from a standardized baseline correlated with fluorescence in situ hybridization-negative status. Patients with greater than 2-log reduction in BCRABL1 level at 3, 6, and 9 months were more likely to achieve major molecular response at 18 months than those with 2-log reduction or less.Conclusions: Our findings support the feasibility of molecular monitoring using PB and suggest that molecular monitoring conducted at a single reliable reference laboratory can adequately track response without invasive BM testing. Our findings are consistent with other work indicating that early response to imatinib predicts favorable long-term outcome.

AB - Context: Although bone marrow (BM) karyotyping has been the standard in monitoring patients with chronic myeloid leukemia, peripheral blood (PB) monitoring methods may be more convenient.Objective: To conduct post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study to evaluate correlations between results of cytogenetic testing and molecular monitoring from BM and PB during the first 18 months of high-dose imatinib therapy, and between early and late molecular responses.Design: Newly diagnosed patients with chronic-phase chronic myeloid leukemia received imatinib 400 mg twice daily and were monitored quarterly for up to 18 months. Cytogenetic testing was performed by karyotyping using BM or by fluorescence in situ hybridization using PB. Molecular testing was performed by quantitative reverse transcriptase polymerase chain reaction using BM and PB.Results: Significant pairwise correlations were found between results obtained by karyotyping, fluorescence in situ hybridization, and quantitative reverse transcriptase polymerase chain reaction using PB or BM (all pairwise correlations <0.8; P >.001). At 12 months, cytogenetic response by karyotyping correlated well with response by fluorescence in situ hybridization. A median 2.579-log reduction in BCR-ABL1 level from a standardized baseline correlated with fluorescence in situ hybridization-negative status. Patients with greater than 2-log reduction in BCRABL1 level at 3, 6, and 9 months were more likely to achieve major molecular response at 18 months than those with 2-log reduction or less.Conclusions: Our findings support the feasibility of molecular monitoring using PB and suggest that molecular monitoring conducted at a single reliable reference laboratory can adequately track response without invasive BM testing. Our findings are consistent with other work indicating that early response to imatinib predicts favorable long-term outcome.

UR - http://www.scopus.com/inward/record.url?scp=84907200628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907200628&partnerID=8YFLogxK

U2 - 10.5858/arpa.2013-0584-OA

DO - 10.5858/arpa.2013-0584-OA

M3 - Article

C2 - 24308645

AN - SCOPUS:84907200628

VL - 138

SP - 1186

EP - 1192

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 9

ER -